Literature DB >> 18505777

Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis.

S Knudsen1, P J Jennum, K Korsholm, S P Sheikh, S Gammeltoft, J L Frederiksen.   

Abstract

There is emerging evidence that multiple sclerosis (MS), the hypothalamic sleep-wake regulating neuropeptide hypocretin-1 (hcrt-1) and the sleep disorder narcolepsy may be connected. Thus, the major pathophysiological component of narcolepsy is lack of hcrt-1. Dysfunction of the hypocretin system has been reported in MS case reports with attacks of hypothalamic lesions, undetectable cerebrospinal fluid (CSF) hcrt-1 and hypersomnia, but not found during remission in small samples. Finally, daytime sleepiness, the major symptom of narcolepsy, is reported in several MS populations, and there are case reports of co-existent narcolepsy and MS. However, it is unknown whether hcrt-1 and daytime sleepiness generally change during MS attacks. We therefore analyzed whether daytime sleepiness (using the Epworth Sleepiness Scale (ESS)) and CSF hcrt-1 levels differed between MS attack and remission, in 48 consecutively referred patients with relapsing-remitting MS (RRMS) or monosymptomatic optic neuritis (MON). Twenty-seven patients were in attack and 21 in remission. ESS was normal both during attacks (5.4 +/- 3.0) and remission (5.8 +/- 2.6), and mean CSF hcrt-1 was normal (456 +/- 41 pg/ml). No statistically significant differences were found between attack and remission. MRI scans revealed no hypothalamic lesions. The results show that the hypocretin system is intact and sleepiness is not typical in RRMS and MON without hypothalamic lesions on MRI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505777     DOI: 10.1177/1352458508088939

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

2.  Diagnosis and management of central hypersomnias.

Authors:  Karel Sonka; Marek Susta
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

3.  Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis.

Authors:  Poul J Jennum; Birgitte R Kornum; Nadia M Issa; Steen Gammeltoft; Niels Tommerup; Niels Morling; Zeynep Tümer; Stine Knudsen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.